Archive: October 01 2020
Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
NextGen CARs: the race is on
In this issue of Blood, Tong et al present the preclinical and clinical development of an optimized, bivalent tandem CD20/CD19 chimeric antigen receptor (CAR) construct (see figure). Preclinically, they demonstrated dual-antigen specificity, enhanced immune synapse formation, and superior antitumor activity in vitro and in vivo in a murine xenograft model compared with alternative constructs generated from the same 2 single-chain variable fragment (scFv) regions derived from Leu-16 (anti-CD20) and FMC63 (anti-CD19) murine monoclonal antibodie.
Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off...
Advances in CAR-T and cellular therapy from EBMT 2020: MSCs, clinical trial upda...
Cell therapy involves the transplantation of viable cells into a patient in order to trigger a medicinal effect. CAR-T is a popular form of cell therapy, specifically immunotherapy, that can use a patient’s own altered immune cells to fight cancer.